RESUMEN
INTRODUCTION: Basal cell carcinoma is the most common cancer. Excisional surgery is associated with a high clearance rate, at the expense of significant functional and aesthetic morbidity, especially within the T-zone or for extensive lesions. We report five-year follow-up outcomes for carbon dioxide laser extirpation of cutaneous basal cell carcinoma, assisted by immediate methyl aminolevulinate photodynamic therapy and cost-benefit considerations. MATERIALS AND METHODS: Retrospective cohort database analysis of adult patients with biopsy-proven primary cutaneous basal cell carcinoma, completing five years of follow-up. Direct per-lesion cost was compared with conventional wide local excision. Patients with morphoeic basal cell carcinoma were excluded. RESULTS: Treated lesions were up to 1% total body surface area and up to 3.8mm (1.38 ± 0.695cm, mean ± standard deviation) in biopsy-proven depth. At the five-year follow-up mark, 93.6% of treated areas remained free of recurrence. Nodular basal cell carcinoma was the most common subtype (41.5%). A mean tumour depth greater than 2 ± 0.872mm was significantly associated with recurrence (Mann-Whitney, p = 0.0487). For a service delivered through the NHS at 2015 prices, we report a 43% saving, equating to a saving of £235 per basal cell carcinoma or a national annualised saving of £70 million by 2025 for the NHS. CONCLUSION: Our results suggest that CO2-assisted photodynamic therapy is non-inferior to excision but may offer better functional and cosmetic preservation at a fraction of the direct like for like cost of operative surgery. Investigation of this method by randomised controlled methodology is warranted.
Asunto(s)
Ácido Aminolevulínico/análogos & derivados , Carcinoma Basocelular/terapia , Procedimientos Quirúrgicos Dermatologicos/métodos , Láseres de Gas/uso terapéutico , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/uso terapéutico , Neoplasias Cutáneas/terapia , Adulto , Anciano , Anciano de 80 o más Años , Ácido Aminolevulínico/economía , Ácido Aminolevulínico/uso terapéutico , Carcinoma Basocelular/economía , Terapia Combinada , Análisis Costo-Beneficio , Procedimientos Quirúrgicos Dermatologicos/economía , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Fotoquimioterapia/economía , Fármacos Fotosensibilizantes/economía , Estudios Retrospectivos , Neoplasias Cutáneas/economía , Resultado del Tratamiento , Reino UnidoAsunto(s)
Accesibilidad a los Servicios de Salud/tendencias , Queratosis Actínica/tratamiento farmacológico , Medicare/economía , Fotoquimioterapia/tendencias , Neoplasias Cutáneas/tratamiento farmacológico , Estudios Transversales , Accesibilidad a los Servicios de Salud/economía , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Humanos , Reembolso de Seguro de Salud/economía , Reembolso de Seguro de Salud/estadística & datos numéricos , Reembolso de Seguro de Salud/tendencias , Queratosis Actínica/economía , Medicare/estadística & datos numéricos , Fotoquimioterapia/economía , Fotoquimioterapia/estadística & datos numéricos , Población Rural/estadística & datos numéricos , Población Rural/tendencias , Neoplasias Cutáneas/economía , Estados Unidos , Población Urbana/estadística & datos numéricos , Población Urbana/tendenciasRESUMEN
Importance: The EVEREST II trial showed that for patients with polypoidal choroidal vasculopathy (PCV), intravitreal ranibizumab in combination with verteporfin photodynamic therapy improves visual acuity relative to ranibizumab monotherapy. However, whether combination therapy is incrementally cost-effective relative to monotherapy during a lifetime is unclear. Objective: To assess the incremental cost-effectiveness of combination therapy compared with ranibizumab monotherapy in patients with PCV. Design, Setting, and Participants: This model-based, economic evaluation used 2018 unit cost data from a tertiary eye hospital in Singapore, first- and second-year outcomes and resource use data from a multicenter trial across various Asian countries (EVEREST II) to model a hypothetical cohort of patients with symptomatic PCV. Scenario analyses and deterministic and probabilistic sensitivity analyses were performed to examine uncertainty. Data were collected from October 2018 through April 2019 and analyzed from March through October 2019. Interventions: This model used data from the EVEREST II trial, in which all participants were given 0.5 mg of intravitreal ranibizumab once every 4 weeks for the first 3 months. Subsequent administration occurred as needed. For participants receiving combination therapy, standard fluence (50 J/cm3) photodynamic therapy with 6-mg/m2 verteporfin was administered once during the first 3 months and thereafter as needed. Main Outcomes and Measures: Incremental cost per quality-adjusted life-year (QALY) gained for combination therapy relative to monotherapy for patients with PCV. Results: In this model based on a cohort of 1000 patients aged 68 years, a patient with PCV incurred a total cost in Singapore dollars (SGD) of 92â¯327 (US $67â¯399) with combination therapy and SGD 92â¯371 (US $67â¯431) with monotherapy during a lifetime horizon, generating a modest cost savings of SGD 44 (US $32) per patient undergoing combination therapy. Lifetime QALYs were estimated to be 7.87 for combination therapy and 7.85 for monotherapy, for an incremental gain of 0.02 QALYs. Combination therapy remained cost-saving or cost-effective in all lifetime scenarios modeled, but during shorter time horizons and at lower monotherapy costs, it may not be cost-effective. Conclusions and Relevance: This study found combination therapy to be a dominant (more effective and less costly) strategy, being similar in costs and slightly more effective than ranibizumab monotherapy during a lifetime horizon. However, decreasing the time horizon to less than 10 years and/or reductions in the cost of monotherapy may result in combination therapy no longer being cost-effective.
Asunto(s)
Inhibidores de la Angiogénesis/administración & dosificación , Inhibidores de la Angiogénesis/economía , Neovascularización Coroidal/tratamiento farmacológico , Neovascularización Coroidal/economía , Costos de los Medicamentos , Fotoquimioterapia/economía , Fármacos Fotosensibilizantes/administración & dosificación , Fármacos Fotosensibilizantes/economía , Ranibizumab/administración & dosificación , Ranibizumab/economía , Verteporfina/administración & dosificación , Verteporfina/economía , Anciano , Inhibidores de la Angiogénesis/efectos adversos , Asia , Neovascularización Coroidal/diagnóstico , Neovascularización Coroidal/fisiopatología , Ahorro de Costo , Análisis Costo-Beneficio , Femenino , Humanos , Inyecciones Intravítreas , Masculino , Fotoquimioterapia/efectos adversos , Fármacos Fotosensibilizantes/efectos adversos , Calidad de Vida , Años de Vida Ajustados por Calidad de Vida , Ranibizumab/efectos adversos , Recuperación de la Función , Factores de Tiempo , Resultado del Tratamiento , Verteporfina/efectos adversos , Agudeza Visual/efectos de los fármacosRESUMEN
BACKGROUND: Daylight photodynamic therapy (DL-PDT) with methyl-5-aminolaevulinate (MAL) is an effective treatment for mild and moderate actinic keratosis (AK). OBJECTIVES: To assess the clinical efficacy, tolerability and cost-effectiveness of 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) compared with MAL in DL-PDT for grade I-II AKs. METHODS: This nonsponsored, prospective randomized double-blind multicentre trial included 69 patients with 767 grade I-II AKs located symmetrically on the face or scalp. A single DL-PDT was given in a randomized split-face design. The primary outcome was clearance of the AKs at 12 months as assessed by a blinded observer. The secondary outcomes were pain, treatment reactions, cosmetic outcome and the cost-effectiveness of the therapy. RESULTS: In the per-patient (half-face) analysis, clearance was better for the BF-200 ALA sides than for those treated with MAL (P = 0·008). In total, BF-200 ALA cleared 299/375 AKs (79·7%) and MAL 288/392 (73·5%) (P = 0·041). The treatment was practically painless with both photosensitizers, the mean pain visual analogue scale being 1·51 for BF-200 ALA and 1·35 for MAL (P = 0·061). Twenty-six patients had a stronger skin reaction on the BF-200 ALA side, seven on the MAL side and 23 displayed no difference (P = 0·001). The cosmetic outcome was excellent or good in > 90% of cases with both photosensitizers (P = 1·000). The cost-effectiveness plane showed that the costs of DL-PDT were similar for both photosensitizers, but the effectiveness was slightly higher for BF-200 ALA. CONCLUSIONS: Our results indicate that BF-200 ALA is more effective than MAL in DL-PDT for grade I-II AKs. BF-200 ALA provides slightly better value for money than MAL.
Asunto(s)
Ácido Aminolevulínico/análogos & derivados , Queratosis Actínica/tratamiento farmacológico , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/administración & dosificación , Anciano , Anciano de 80 o más Años , Ácido Aminolevulínico/administración & dosificación , Ácido Aminolevulínico/efectos adversos , Ácido Aminolevulínico/economía , Análisis Costo-Beneficio , Femenino , Humanos , Queratosis Actínica/diagnóstico , Masculino , Persona de Mediana Edad , Fotoquimioterapia/efectos adversos , Fotoquimioterapia/economía , Fármacos Fotosensibilizantes/efectos adversos , Fármacos Fotosensibilizantes/economía , Estudios Prospectivos , Resultado del TratamientoRESUMEN
BACKGROUND: The cost of topical treatments for actinic keratosis (AK) has never been evaluated with respect to the actual cancerization field treated and the corresponding lesion response rate. Traditionally, evaluation in AK has been done in the context of patient response rate alone. The current study aimed to develop an economic model assessing the cost of topical treatments for the management of AK in Italy. METHODS: Data from Italian patients (N.=100) with five or more mild/moderate lesions on the face and/or scalp was used. The efficacy of the topical treatments which are available for the treatment of AK in Italy was considered. The outcome of interest was lesion response rates at three months and was based on published literature. The cost of each treatment was estimated according to the approval status of the drug and the cancerization area that required treatment. The analysis was replicated for four other European countries. RESULTS: The average costs of treatment with c-PDT, DL PDT, DHA, InMeb and IMQ were 364.2, 255.5, 848.7, 1039.1, and 628.3, respectively. Taking into account the number of lesions cleared per patient, the cancerization area treated, and the number of visits required with each treatment, the total costs per lesion treated per patient were estimated at 37.9, 29, 264.7, 103.5, and 115.4, respectively. The analysis produced consistent results when it was replicated for other countries. CONCLUSIONS: Daylight therapy with methyl aminolevulinate (DL PDT) is an effective treatment option for AK management with a favourable value for money profile.
Asunto(s)
Ácido Aminolevulínico/análogos & derivados , Queratosis Actínica/tratamiento farmacológico , Modelos Económicos , Fotoquimioterapia/métodos , Administración Cutánea , Ácido Aminolevulínico/administración & dosificación , Ácido Aminolevulínico/economía , Europa (Continente) , Humanos , Italia , Queratosis Actínica/economía , Fotoquimioterapia/economía , Fármacos Fotosensibilizantes/administración & dosificación , Fármacos Fotosensibilizantes/economía , Resultado del TratamientoAsunto(s)
Terapia por Láser/economía , Fotoquimioterapia/economía , Enfermedades de la Piel/tratamiento farmacológico , Ácido Aminolevulínico/administración & dosificación , Ácido Aminolevulínico/economía , Humanos , Terapia por Láser/métodos , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/administración & dosificación , Fármacos Fotosensibilizantes/economíaRESUMEN
Photodynamic therapy (PDT) is a promising treatment for oral candidoses. Its use as an alternative to antifungals prevents several adverse effects, including microbial resistance. However, most PDT protocols do not employ devices and consumables commonly available in dental practice, thus influencing treatment affordability. This study aimed to determine the efficacy of a PDT method based on light curing units' blue LEDs combined to a plaque-disclosing composition (5% erythrosine) against C. albicans in culture and in a murine model of oral candidosis. Standard and resistant fungal strains were tested in vitro in planktonic and biofilm forms. PDT (pre-irradiation time periods: 30 and 60 s; irradiation time: 3 min) was compared to control conditions without light and/or erythrosine. Mice with induced oral candidosis (n = 40) randomly received PDT or similar control conditions with subsequent C. albicans count. These mice underwent histological analysis, as well as 12 healthy mice submitted to experimental treatments. PDT completely inactivated C. albicans planktonic cells and biofilm. Control conditions presented minor differences (ANOVA, p < 0.05), with mean values ranging from 5.2 to 6.8 log10 (UFC/mL). Infected mice presented no significant difference in C. albicans counts consequent to treatments (ANOVA, p = 0.721), although the PDT protocol was able to enhance the inflammatory infiltrate in healthy mice. It can be concluded that the tested PDT protocol can inactivate C. albicans but still needs further investigation in order to achieve efficacy and safety.
Asunto(s)
Candidiasis Bucal/tratamiento farmacológico , Candidiasis Bucal/economía , Análisis Costo-Beneficio , Fotoquimioterapia/economía , Fotoquimioterapia/métodos , Animales , Antifúngicos/farmacología , Biopelículas/efectos de los fármacos , Biopelículas/efectos de la radiación , Candida albicans/efectos de los fármacos , Candida albicans/crecimiento & desarrollo , Candida albicans/efectos de la radiación , Candidiasis Bucal/microbiología , Eritrosina/farmacología , Eritrosina/uso terapéutico , Inflamación/patología , Masculino , Ratones , Fármacos Fotosensibilizantes/farmacología , Plancton/efectos de los fármacos , Plancton/efectos de la radiaciónRESUMEN
PURPOSE: To evaluate the cost effectiveness of corneal collagen crosslinking (CXL) for progressive keratoconus from the healthcare payer's perspective. DESIGN: A probabilistic Markov-type model using data from published clinical trials and cohort studies. PARTICIPANTS: Two identical cohorts, each comprising 1000 virtual patients with progressive bilateral keratoconus, were modeled; one cohort underwent CXL and the other cohort received no intervention. METHODS: Both cohorts were modeled and evaluated annually over a lifetime. Quality-adjusted life years (QALYs), total cost, disease progression, and the probability of corneal transplantation, graft failure, or both were calculated based on data from published trials and cohort studies. These outcomes were compared between the 2 cohorts. In our base scenario, the stabilizing effect of CXL was assumed to be 10 years; however, longer durations also were analyzed. One-way sensitivity analyses were performed to test the robustness of the outcomes. MAIN OUTCOME MEASURE: Incremental cost-effectiveness ratio (ICER), defined as euros per QALY. RESULTS: Assuming a 10-year effect of CXL, the ICER was 54 384/QALY ($59 822/QALY). When we adjusted the effect of CXL to a lifelong stabilizing effect, the ICER decreased to 10 149/QALY ($11 163/QALY). Other sensitivity and scenario analyses that had a relevant impact on ICER included the discount rate, visual acuity before CXL, and healthcare costs. CONCLUSIONS: Corneal collagen crosslinking for progressive keratoconus is cost effective at a willingness-to-pay threshold of 3 times the current gross domestic product (GDP) per capita. Moreover, a longer stabilizing effect of CXL increases cost effectiveness. If CXL had a stabilizing effect on keratoconus of 15 years or longer, then the ICER would be less than the 1 × GDP per capita threshold and thus very cost effective.
Asunto(s)
Colágeno/metabolismo , Sustancia Propia/metabolismo , Análisis Costo-Beneficio , Reactivos de Enlaces Cruzados/economía , Queratocono/economía , Fotoquimioterapia/economía , Fármacos Fotosensibilizantes/economía , Adulto , Trasplante de Córnea , Progresión de la Enfermedad , Estudios de Seguimiento , Costos de la Atención en Salud , Humanos , Queratocono/tratamiento farmacológico , Queratocono/metabolismo , Cadenas de Markov , Persona de Mediana Edad , Años de Vida Ajustados por Calidad de Vida , Riboflavina/economía , Rayos Ultravioleta , Agudeza Visual/fisiología , Adulto JovenRESUMEN
PURPOSE: To use patient-level microsimulation models to evaluate the comparative cost-effectiveness of early corneal cross-linking (CXL) and conventional management with penetrating keratoplasty (PKP) when indicated in managing keratoconus in Canada. DESIGN: Cost-utility analysis using individual-based, state-transition microsimulation models. PARTICIPANTS: Simulated cohorts of 100 000 individuals with keratoconus who entered each treatment arm at 25 years of age. Fellow eyes were modeled separately. Simulated individuals lived up to a maximum of 110 years. METHODS: We developed 2 state-transition microsimulation models to reflect the natural history of keratoconus progression and the impact of conventional management with PKP versus CXL. We collected data from the published literature to inform model parameters. We used realistic parameters that maximized the potential costs and complications of CXL, while minimizing those associated with PKP. In each treatment arm, we allowed simulated individuals to move through health states in monthly cycles from diagnosis until death. MAIN OUTCOME MEASURES: For each treatment strategy, we calculated the total cost and number of quality-adjusted life years (QALYs) gained. Costs were measured in Canadian dollars. Costs and QALYs were discounted at 5%, converting future costs and QALYs into present values. We used an incremental cost-effectiveness ratio (ICER = difference in lifetime costs/difference in lifetime health outcomes) to compare the cost-effectiveness of CXL versus conventional management with PKP. RESULTS: Lifetime costs and QALYs for CXL were estimated to be Can$5530 (Can$4512, discounted) and 50.12 QALYs (16.42 QALYs, discounted). Lifetime costs and QALYs for conventional management with PKP were Can$2675 (Can$1508, discounted) and 48.93 QALYs (16.09 QALYs, discounted). The discounted ICER comparing CXL to conventional management was Can$9090/QALY gained. Sensitivity analyses revealed that in general, parameter variations did not influence the cost-effectiveness of CXL. CONCLUSIONS: CXL is cost-effective compared with conventional management with PKP in the treatment of keratoconus. Our ICER of Can$9090/QALY falls well below the range of Can$20 000 to Can$100 000/QALY and below US$50 000/QALY, thresholds generally used to evaluate the cost-effectiveness of health interventions in Canada and the United States. This study provides strong economic evidence for the cost-effectiveness of early CXL in keratoconus.
Asunto(s)
Colágeno/metabolismo , Sustancia Propia/metabolismo , Análisis Costo-Beneficio , Reactivos de Enlaces Cruzados/economía , Queratocono/economía , Fotoquimioterapia/economía , Fármacos Fotosensibilizantes/economía , Adulto , Canadá , Simulación por Computador , Humanos , Queratocono/tratamiento farmacológico , Queratocono/metabolismo , Queratoplastia Penetrante/economía , Modelos Económicos , Fármacos Fotosensibilizantes/uso terapéutico , Años de Vida Ajustados por Calidad de Vida , Riboflavina/economía , Riboflavina/uso terapéutico , Rayos UltravioletaRESUMEN
Photodynamic therapy (PDT), using topical aminolevulinic acid (ALA), has been used for years to treat a variety of dermatologic conditions, including actinic keratosis, superficial basal cell carcinoma, and in situ squamous cell carcinoma. While there is a wide range of neoplastic and non-neoplastic skin diseases for which ALA-PDT is used in adults, there is a knowledge gap when it comes to its use in children. This review highlights what is currently known regarding the use and efficacy of this therapy in the pediatric population. A PubMed search was conducted to identify studies including pediatric patients undergoing monotherapy PDT with topical aminolevulinate (published 2005-2016). Twenty pediatric articles were identified. ALA-PDT has been used successfully in children to reduce the number and size of basal cell tumors, inflammatory acne lesions, plantar warts, and linear porokeratoses. ALA-PDT may be an attractive alternative to surgery for children with basal cell nevus syndrome, or to conventional destructive and/or topical methods used for plantar warts or linear porokeratoses. PDT can be considered for inflammatory acne when topical treatments have failed and systemic medications are not an option. Pain associated with treatment and insurance coverage may be a barrier to use.
Asunto(s)
Acné Vulgar/tratamiento farmacológico , Ácido Aminolevulínico/uso terapéutico , Fotoquimioterapia , Fármacos Fotosensibilizantes/uso terapéutico , Poroqueratosis/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Verrugas/tratamiento farmacológico , Adolescente , Niño , Preescolar , Humanos , Lactante , Recién Nacido , Fotoquimioterapia/efectos adversos , Fotoquimioterapia/economíaRESUMEN
Some basal cell carcinomas (BCCs) are indistinguishable from nevi based on clinical manifestations. Therefore, it is often difficult for the excision margins of the initial surgical treatment to achieve radical removal of the malignancy. This study was a comparative analysis of the clinical results of aminolevulinic acid (ALA)-photodynamic therapy (PDT) or secondary surgery after the primary excision. In total, 20 patients with preoperative clinical diagnoses of nevi underwent in situ resection. The postoperative pathological diagnoses confirmed all cases were BCC. Ten patients received PDT twice after the primary excision, and 10 cases received extended resection after the primary excision. Patients were followed up for 8 months at least, and the 2 groups did not show statistically significant differences in the recurrence rate, while the PDT group had better results in terms of economic burden, healing period, and cosmetic satisfaction than the group with secondary surgery. Our study demonstrates that ALA-PDT can sever as a considerable remedial treatment for the BCC patients who have not accepted radical resection due to primary clinical misdiagnosis.
Asunto(s)
Ácido Aminolevulínico/uso terapéutico , Carcinoma Basocelular/terapia , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/uso terapéutico , Neoplasias Cutáneas/terapia , Adulto , Anciano , Anciano de 80 o más Años , Ácido Aminolevulínico/economía , Carcinoma Basocelular/cirugía , Supervivencia sin Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Satisfacción del Paciente , Fotoquimioterapia/economía , Fármacos Fotosensibilizantes/economía , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/cirugía , Cicatrización de HeridasRESUMEN
Actinic keratosis is one of the most common dermatological diagnoses worldwide, especially among the elderly, fair-skinned, and immunocompromised, and is associated with a risk of transformation to skin cancer. With actinic keratosis and skin cancer prevalence increasing as the aged population expands in the US, optimizing treatment strategies may produce cost savings for the healthcare system. Since the time of our last review in 2008, investigation of the economic considerations in treating actinic keratosis has advanced. To provide an update of treatment cost effectiveness and to review factors relating to the costs of care, we conducted a systematic review of pharmacoeconomic publications since December 2008. We identified 11 pharmacoeconomic studies, with one cost-of-treatment, five cost-effectiveness, and five cost-utility analyses. Photodynamic therapy (PDT) was well tolerated and produced a favorable cosmetic outcome in most studies. Ingenol mebutate, the newest but most expensive topical field therapy, 5-fluorouracil, and PDT were the most cost-effective treatments in our review. Patient adherence to therapy and the management of adverse effects were significant contributors to treatment costs. In the US, treatment guidelines and formalized cost-effectiveness analyses for actinic keratosis are absent from the recent literature. Future pharmacoeconomic investigation will depend on up-to-date comparative efficacy data, as well as clarification of rates of, and management strategies for, adverse effects, therapeutic non-adherence, and lesion recurrence.
Asunto(s)
Fármacos Dermatológicos/administración & dosificación , Queratosis Actínica/tratamiento farmacológico , Fotoquimioterapia/métodos , Anciano , Análisis Costo-Beneficio , Fármacos Dermatológicos/efectos adversos , Fármacos Dermatológicos/economía , Economía Farmacéutica , Humanos , Queratosis Actínica/complicaciones , Queratosis Actínica/economía , Cumplimiento de la Medicación , Fotoquimioterapia/efectos adversos , Fotoquimioterapia/economía , Guías de Práctica Clínica como Asunto , Factores de Riesgo , Neoplasias Cutáneas/etiología , Neoplasias Cutáneas/prevención & controlRESUMEN
BACKGROUND: Surgical resection of high-grade gliomas (HGG) is standard therapy because it imparts significant progression free (PFS) and overall survival (OS). However, HGG-tumor margins are indistinguishable from normal brain during surgery. Hence intraoperative technology such as fluorescence (ALA, fluorescein) and intraoperative ultrasound (IoUS) and MRI (IoMRI) has been deployed. This study compares the effectiveness and cost-effectiveness of these technologies. METHODS: Critical literature review and meta-analyses, using MEDLINE/PubMed service. The list of references in each article was double-checked for any missing references. We included all studies that reported the use of ALA, fluorescein (FLCN), IoUS or IoMRI to guide HGG-surgery. The meta-analyses were conducted according to statistical heterogeneity between studies. If there was no heterogeneity, fixed effects model was used; otherwise, a random effects model was used. Statistical heterogeneity was explored by χ2 and inconsistency (I2) statistics. To assess cost-effectiveness, we calculated the incremental cost per quality-adjusted life-year (QALY). RESULTS: Gross total resection (GTR) after ALA, FLCN, IoUS and IoMRI was 69.1%, 84.4%, 73.4% and 70% respectively. The differences were not statistically significant. All four techniques led to significant prolongation of PFS and tended to prolong OS. However none of these technologies led to significant prolongation of OS compared to controls. The cost/QALY was $16,218, $3181, $6049 and $32,954 for ALA, FLCN, IoUS and IoMRI respectively. CONCLUSIONS: ALA, FLCN, IoUS and IoMRI significantly improve GTR and PFS of HGG. Their incremental cost was below the threshold for cost-effectiveness of HGG-therapy, denoting that each intraoperative technology was cost-effective on its own.
Asunto(s)
Neoplasias Encefálicas/economía , Neoplasias Encefálicas/cirugía , Glioma/economía , Glioma/cirugía , Fotoquimioterapia/economía , Cirugía Asistida por Computador/economía , Ácido Aminolevulínico/economía , Neoplasias Encefálicas/diagnóstico , Medios de Contraste/economía , Análisis Costo-Beneficio/estadística & datos numéricos , Fluoresceína/economía , Glioma/diagnóstico , Costos de la Atención en Salud/estadística & datos numéricos , Humanos , Imagen por Resonancia Magnética/economía , Márgenes de Escisión , Microscopía Fluorescente/economía , Monitoreo Intraoperatorio/economía , Clasificación del Tumor , Prevalencia , Resultado del Tratamiento , Ultrasonografía/economíaAsunto(s)
Sustancia Propia/metabolismo , Reactivos de Enlaces Cruzados/economía , Costos de la Atención en Salud/estadística & datos numéricos , Queratocono/economía , Fotoquimioterapia/economía , Colágeno/metabolismo , Costo de Enfermedad , Análisis Costo-Beneficio , Costos de los Medicamentos , Femenino , Humanos , Queratocono/tratamiento farmacológico , Queratocono/metabolismo , Masculino , Fármacos Fotosensibilizantes/economía , Riboflavina/economía , Rayos Ultravioleta , Agudeza Visual/fisiología , Adulto JovenRESUMEN
Actinic keratoses (AK) occur frequently; however, real-life clinical data on personalized treatment choice and costs are scarce. This multicentre one-year observational study investigated patient-characteristics, cost and effectiveness of methylaminolaevulinate photodynamic therapy (MAL-PDT), imiquimod (IMI) and 5-fluorour-acil (5-FU) in patients with AKs on the face/scalp. A total of 104 patients preferred MAL-PDT, 106 preferred IMI and 110 preferred 5-FU. At baseline, significant differences between treatment groups were found; most patients were severely affected (mean 32.5 AK in PDT-group, 20.2 in IMI-group, 22.8 in 5-FU-group). A mean reduction in lesions of 81% after MAL-PDT, 82% after IMI and 88% after 5-FU was found after one year. Annual costs were 1,950 for MAL-PDT, 877 for IMI and 738 for 5-FU. These results show that, compared with clinical trials, in the real-life clinical setting AK patients are usually more severely affected and treatment costs are much higher. Furthermore, patient characteristics are important factors in treatment choice.
Asunto(s)
Ácido Aminolevulínico/análogos & derivados , Aminoquinolinas/economía , Aminoquinolinas/uso terapéutico , Fármacos Dermatológicos/economía , Fármacos Dermatológicos/uso terapéutico , Costos de los Medicamentos , Fluorouracilo/economía , Fluorouracilo/uso terapéutico , Queratosis Actínica/tratamiento farmacológico , Queratosis Actínica/economía , Fotoquimioterapia/economía , Fármacos Fotosensibilizantes/economía , Fármacos Fotosensibilizantes/uso terapéutico , Anciano , Anciano de 80 o más Años , Ácido Aminolevulínico/economía , Ácido Aminolevulínico/uso terapéutico , Análisis Costo-Beneficio , Femenino , Humanos , Imiquimod , Masculino , Persona de Mediana Edad , Países Bajos , Prioridad del Paciente , Fotoquimioterapia/métodos , Inducción de Remisión , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del TratamientoRESUMEN
Daylight-mediated photodynamic therapy (DL-PDT) is considered as effective as conventional PDT using artificial light (light-emitting diode (LED)-PDT) for treatment of actinic keratoses (AK). This randomized prospective non-sponsored study assessed the cost-effectiveness of DL-PDT compared with LED-PDT. Seventy patients with 210 AKs were randomized to DL-PDT or LED-PDT groups. Effectiveness was assessed at 6 months. The costs included societal costs and private costs, including the time patients spent in treatment. Results are presented as incremental cost-effectiveness ratio (ICER). The total costs per patient were significantly lower for DL-PDT (132) compared with LED-PDT (170), giving a cost saving of 38 (p = 0.022). The estimated probabilities for patients' complete response were 0.429 for DL-PDT and 0.686 for LED-PDT; a difference in probability of being healed of 0.257. ICER showed a monetary gain of 147 per unit of effectiveness lost. DL-PDT is less costly and less effective than LED-PDT. In terms of cost-effectiveness analysis, DL-PDT provides lower value for money compared with LED-PDT.
Asunto(s)
Costos de la Atención en Salud , Helioterapia/economía , Queratosis Actínica/economía , Queratosis Actínica/terapia , Fotoquimioterapia/economía , Fotoquimioterapia/instrumentación , Anciano , Anciano de 80 o más Años , Ahorro de Costo , Análisis Costo-Beneficio , Femenino , Helioterapia/efectos adversos , Humanos , Queratosis Actínica/diagnóstico , Masculino , Persona de Mediana Edad , Fotoquimioterapia/efectos adversos , Estudios Prospectivos , Factores de Tiempo , Resultado del TratamientoRESUMEN
Age-related macular degeneration (AMD) is a common ophthalmic condition that can have few symptoms in its early stage but can progress to major visual impairment. While there are no treatments for early-stage AMD, there are multiple modalities of treatment for advanced disease. Given the increasing prevalence of the disease, there are dozens of analyses of cost effectiveness of AMD treatments, but methods and approaches vary broadly. The goal of this review was to identify, characterize, and critique published models in AMD and provide guidance for their interpretation. After a literature review was performed to identify studies, and exclusion criteria applied to limit the review to studies comparing treatments for AMD, we compared methods across the 36 studies meeting the review criteria. To some extent, variation was related to targeting different audiences or acknowledging the most appropriate population for a given treatment. However, the review identified potential areas of uncertainty and difficulty in interpretation, particularly regarding duration of observation periods and the importance of visual acuity as an endpoint or a proxy for patient-reported utilities. We urge thoughtful consideration of these study characteristics when comparing results.
Asunto(s)
Inhibidores de la Angiogénesis/economía , Inhibidores de la Angiogénesis/uso terapéutico , Análisis Costo-Beneficio/métodos , Análisis Costo-Beneficio/normas , Degeneración Macular/economía , Degeneración Macular/terapia , Modelos Económicos , Factores de Edad , Humanos , Degeneración Macular/tratamiento farmacológico , Fotoquimioterapia/economía , Años de Vida Ajustados por Calidad de Vida , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Agudeza Visual/efectos de los fármacosRESUMEN
BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer in the United States. Cutaneous squamous cell carcinoma has an estimated incidence of more than 700,000 new cases per year and a 5% risk of metastasis. OBJECTIVE: To provide clinicians with guidelines for the management of cSCC based on evidence from a comprehensive literature review and consensus among the authors. MATERIALS AND METHODS: The authors conducted an extensive review of the medical literature on treatment methods for cSCC, taking into consideration cure rates, recurrence and metastatic rates, aesthetic and functional outcomes, and cost effectiveness of the procedures. RESULTS: Surgical treatments provide the best outcomes for cSCC. Mohs micrographic surgery is a cost-effective procedure that affords the highest cure rate, maximal tissue preservation, and superior cosmetic outcomes. Nonsurgical methods may be used as a primary treatment for low-risk squamous cell carcinomas, but the cure rates are lower. CONCLUSION: The cure rate remains the most important consideration in choosing the treatment method, but additional factors, such as the patient's general medical condition, psychosocial circumstances, the location of the tumor and cost effectiveness of the therapy should be considered. Mohs micrographic surgery remains the preferred treatment for high-risk tumors and tumors located in cosmetically sensitive areas.
Asunto(s)
Carcinoma de Células Escamosas/terapia , Neoplasias Cutáneas/terapia , Administración Cutánea , Antineoplásicos/administración & dosificación , Antineoplásicos/economía , Carcinoma de Células Escamosas/economía , Carcinoma de Células Escamosas/epidemiología , Carcinoma de Células Escamosas/etiología , Carcinoma de Células Escamosas/patología , Consenso , Análisis Costo-Beneficio , Crioterapia/economía , Medicina Basada en la Evidencia , Humanos , Huésped Inmunocomprometido , Incidencia , Cirugía de Mohs/economía , Fotoquimioterapia/economía , Radioterapia/economía , Factores de Riesgo , Neoplasias Cutáneas/economía , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/etiología , Neoplasias Cutáneas/patología , Estados Unidos/epidemiologíaRESUMEN
BACKGROUND: A large number of treatments for peri-implantitis are available, but their cost-effectiveness remains uncertain. This study evaluates the cost-effectiveness of preventing and treating peri-implantitis. METHODS: A Markov model was constructed that followed each implant over 20 years. Supportive implant therapy (SIT) for managing peri-implant mucositis and preventing development of peri-implantitis was either provided or not. Risk of peri-implantitis was assumed to be affected by SIT and the patient's risk profile. If peri-implantitis occurred, 11 treatment strategies (non-surgical or surgical debridement alone or combined with adjunct therapies) were compared. Treatments and risk profiles determined disease progression. Modeling was performed based on systematically collected data. Primary outcomes were costs and proportion of lost implants, as assessed via Monte Carlo microsimulations. RESULTS: Not providing SIT and performing only non-surgical debridement was both least costly and least effective. The next best (more costly and effective) option was to provide SIT and perform surgical debridement (additional 0.89 euros per 1% fewer implants lost). The most effective option included bone grafts, membranes, and laser treatment (56 euros per 1%). For patients at high risk, the cost-effectiveness of SIT increased, whereas in low-risk groups, a cost-optimized strategy was cost-effective. CONCLUSIONS: Although clinical decision-making will be guided mainly by clinical condition, cost-effectiveness analyses might add another perspective. Based on these findings, an unambiguous comparative effectiveness ranking was not established. However, cost-effectiveness was predominantly determined by provision of SIT and initial treatment costs. Transferability of these findings to other healthcare systems needs further confirmation.